Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Brownback Wants FDA To Aggressively Coordinate Drug Development For Neglected/Rare Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

The Kansas Republican suggests the agency could get all parties, including investors, into the action to push therapies past the approval goal posts.
Advertisement

Related Content

FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD
FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD
Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
Rare Disease Improvements Planned Soon, And Up To Five Years From Now
Rare Disease Improvements Planned Soon, And Up To Five Years From Now
FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less
Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone
Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Topics

Advertisement
UsernamePublicRestriction

Register

PS070807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel